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Abstract
High plasma uric acid (UA) is a precipitating factor for gout and renal calculi as well as a strong risk factor for
Metabolic Syndrome and cardiovascular disease. The main causes for higher plasma UA are either lower excretion,
higher synthesis or both. Higher waist circumference and the BMI are associated with higher insulin resistance and
leptin production, and both reduce uric acid excretion. The synthesis of fatty acids (tryglicerides) in the liver is
associated with the de novo synthesis of purine, accelerating UA production. The role played by diet on
hyperuricemia has not yet been fully clarified, but high intake of fructose-rich industrialized food and high alcohol
intake (particularly beer) seem to influence uricemia. It is not known whether UA would be a causal factor or an
antioxidant protective response. Most authors do not consider the UA as a risk factor, but presenting antioxidant
function. UA contributes to > 50% of the antioxidant capacity of the blood. There is still no consensus if UA is a
protective or a risk factor, however, it seems that acute elevation is a protective factor, whereas chronic elevation a
risk for disease.
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Introduction
High plasma uric acid (UA) is a prerequisite for gout
and is also associated with the Metabolic Syndrome and
risk factors for cardiovascular diseases [1-4]. Hyperurice-
mia increase in 16% all causes of mortality and 39% of
total cardiovascular disease [5].
The hyperuricemia is defined as ≥7m g / d Lf o rm e n
and ≥6.0 mg/dL for women [6], and is found mainly in
postmenopausal women, African American, patients
with renal disease and alcohol intake [7]. Furthermore,
many factors can influence the concentrations of UA,
eg. diet, obesity, and Metabolic Syndrome [1,8-10].
However, we still don’t know if UA is a protective factor
for the moderate oxidative stress in these situations or if
it’s a risk factor.
The aim of this review was to discuss the function of
the UA in our organism and the main causes and conse-
quences of the higher concentration of UA.
Chemical characterization and biological
importance
Uric acid (2,6,8 trioxypurine-C5H4N4O3) is an organic
compound that is endogenously produced by animals as
a purine metabolite. It is formed by the liver and mainly
excreted by the kidneys (65-75%) and intestines (25-
35%). UA is the end product of purine metabolism in
humans due to the loss of uricase activity, which led to
humans having higher UA levels than other mammals
[11,12].
Due to its double bonds, uric acid has excellent anti-
oxidant capacity, and it can be responsible for 2/3 of
total plasma antioxidant capacity [13,14].
Because it is a weak acid that have a high dissociation
constant, uric acid circulates in plasma (pH 7.4) predo-
minantly (98%) in the form of a monovalent sodium salt
(urate) [15]. It shows low solubility in water (as well as
in plasma), and it would theoretically reach plasma
saturation in the concentration of 6.4 mg/dL, which
may not occur because solubility increase is provided by
its binding to proteins, namely albumin, which is its
main transporter. Protein-bound uric acid shows plasma
solubility that is 70% higher than in its free state [16]. * Correspondence: erick_po@yahoo.com.br
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arthritis or nephrolithiasis [12].
High uricemia pathogenicity is associated with its low
solubility in the extracellular environment leading to
crystal formation, low affinity (and deposition) to certain
tissues and antigenicity (after crystal phagocytosis). This
mixture of quantitative and qualitative etiological hyper-
uricemia factors is confounding because normouricemic
individuals may show symptoms while others with
hyperuricemia may not. In the clinical context, hyperuri-
cemia is seen as a prognostic indicator of renal disease,
diabetes mellitus, cardiovascular disease and inflamma-
tion [7,17-23], thus being a (modest) risk factor for mor-
tality [1].
Uricemia homeostasis
Physiologically, uric acid plasma concentrations
increases with age; they are smaller in women of child-
bearing age and, in post menopause women, it increase
to similar values to those found in males [2,3].
The balance between uric acid production and excre-
tion in males shows a turnover of 600- 700 mg/day for
a pool with a maximum of 1,000 mg, as shown by isoto-
pic studies. Uric acid entry into the pool is controlled
by hepatic production, which receives endogenous
(nucleoproteins) and exogenous (dietary) precursor pro-
teins. Uric acid exit from the pool in males is mainly
controlled by the kidneys and by urine-forming factors,
renal plasma flow, glomerular filtration and tubular
exchange [24,25].
Excretion control
In the kidney, uric acid and urate are initially filtered
and additionally secreted. However, the largest part
(90%) is usually reabsorbed and returns to blood [12].
The factors that can influence the uptake of urate by
t h ek i d n e ya r e :p l a s m ac o n c e n t r a t i o n s ,v o l e m i aa n d
renal plasma flow modulators. At this point, renal excre-
tion of urate follows the same extra-renal limiting fac-
tors as those of glomerular filtration. Kidney
participation is associated with glomerular filtration
(90% filtrate), proximal reabsorption (by an active pro-
cess) and post-secretory resorption in the distal tubule,
ascending loop and collecting duct. In this phase, the
renal excretion of urate follows the limiting factors that
accompany renal diseases (glomerular and medullary).
The urate renal excretion phase is that of post-secretory
resorption [24].
Proximal tubular reabsorption of uric acid is competi-
tive with monocarboxylic organic acids, and it can be
inhibited by oxalic acid, lactic acid and ketone bodies
(acetoacetic and beta-hydroxybutyric acids). Metabolic
situations with higher production and circulation of
such acids are accompanied by the hypoexcretion of
uric acid in urine [24].
Lactic acid is a product of anaerobic glycolysis
(NADH-dependent) in alcoholics, resulting from the
metabolism of ethanol (due to higher NADH produc-
tion), and in inflammation/infection (due to PDH inhibi-
tion by pro-inflammatory cytokines) [24].
Ketone bodies are produced in the liver by partial oxi-
dation of acetyl coenzyme A due to excessive peripheral
lipolysis. Ketonuria occurs in decompensated diabetic
individuals and in acute fasting (weight loss by carbohy-
drate-restricted diets). Factors that increase uric acid
urinary excretion: extracellular volume expansion and
tubular resorption inhibition [24].
Acute renal failure can also rise UA by decreased of
renal excretion [26]. Furthermore, the consumption of
some drugs are associated with the raise of serum UA
(ciclosporin, ethambutol, pyrazinamide, cytotoxic che-
motherapy). On the other hand, other drugs (benzbro-
marone, losartan, probenecid, sulfinpyrazon) diminishes
the UA concentration mainly by the inhibition of a spe-
cific anion transporters (URAT1), that is responsible for
the reabsorption of renal uric acid, which explain the
uricosuric effect of these drugs [2].
Production control
Purine bases and their nucleotides are rapidly captured
by the liver [27] and converted into xanthines, metabo-
l i z e db yu r i ca c i do rr e c y c l e db ys a l v a g ep a t h w a y so rde
novo synthesis, and the latter requires a higher energetic
cost (ATP consumption) [28]. Uric acid formation by
xanthine occurs via hypoxanthine by the action of
xanthine oxidase [29]. In most mammals, uric acid is
converted into allantoin by uricase and later into urea,
which are excreted. For this reason, uricemia in these
animals corresponds to 10% of human values [30,31].
Diseases accompanied by great cell depletion, such as
leukemia, leukocytosis and dystrophies can increase the
provision of nucleic acids to the liver and result in a lar-
ger production of uric acid. Hence, diseases resulting
from innate purine metabolic errors may also result in
hyperuricemia [2,3,12].
Diet
The relation between diet and UA has not yet been fully
clarified since most studies have not estimated basal
urate concentrations, have not excluded confounding
factors or have not even correctly evaluated ingested
nutrients [32].
The human diet is very poor in urate, which is pro-
duced mainly in the liver and to a less extent in the
small intestine. The production of UA depends of pur-
ine ingestion [2], however, a purine-rich diet would be
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UA [33,34].
It is recommended that individuals with hyperuricemia
should not ingest a large amount of purine-rich food
(for instance, veal, bacon, kid meat, mutton, turkey,
pork, duck, goose, etc.) [35], and it is suggested that a
high intake of meat and seafood are related to increased
UA, but the same relation is not valid for total protein
intake [36].
During fructose metabolism, the phosphorylation of
such monosaccharide into fructose 1-phosphate occurs
by means of enzyme fructokinase. Next, enzyme aldolase
B breaks fructose 1-phosphate into dihydroxyacetone
phosphate (DHAP) and D-glyceraldehyde. When high
fructose intake occurs, fructose phosphorylation into
fructose 1-phosphate is fast, but the reaction with aldo-
lase is slow. Hence, fructose 1-phosphate accumulates,
and inorganic concentrations of intracellular phosphate
also decrease. The low availability of phosphate limits
ATP formation (ADP + Pi), and ADP or AMP resulting
from such metabolism is catabolized, thus leading to
hyperuricemia [37].
There are other ways to increase urate concentrations,
such as the intake of sorbitol, sucrose, lactate and
methylxanthines [38]. After absorption, sorbitol is con-
verted into fructose by the liver, and thus, it can
increase UA production [39,40].
Fruit and vegetables, in addition to flavonoids, can
contain other nutrients that can affect the plasma total
antioxidant capacity (TAC). Lotito & Frei (2006) [40]
reported that the TAC increase observed after the intake
of these flavonoid-rich food types is not specifically
caused by flavonoids because such nutrients are prob-
ably highly metabolized after ingestion. Possibly, what
would increase TAC would be the UA elevation result-
ing from fructose metabolism. The mechanism for such
elevation would be the degradation of purine nucleo-
tides or UA excretion reduction [41-43].
High vitamin-C intake shows an inverse relation with
UA [44] as such vitamin has a uricosuric effect due to
competition of UA renal resorption through a change in
the anion transportation system in the proximal tubule
[45,46].
Beer intake is an independent factor from UA increase
[32] both due to its alcoholic content and high-quality
purine [47]. Beer intake has a stronger power to increase
UA than liqueur, but moderate wine intake does not
increase UA [36,48]. Alcohol intake increases UA con-
centrations by reducing excretion [49,50] and increasing
urate production [51].
Dairy product intake has an inverse relation with UA
[32,36,52]. Probably, the mechanism for such association
is due to milk-forming proteins (lactalbumin and
casein), which have a uricosuric effect [53].
There is an inverse relation between coffee intake and
UA concentrations [48], but such association seems to
be due to other substances, as it does not seem to result
from caffeine. Decreased UA concentrations would
result from the improved insulin resistance observed
with increased coffee intake, which occurs mainly due
to chlorogenic acid, an antioxidant found in that drink
[54,55].
Tsunoda et al. (2002) [56] observed the effects of
hypocaloric diets on uric acid in overweight individuals.
This type of diet indirectly decreased UA serum concen-
trations because it improved insulin sensitivity in these
individuals, and this occurred regardless of changes in
body weight or blood pressure.
Uricemia as a risk factor
Gouty arthritis
Gout is caused by articulation deposition of monoso-
dium urate crystals after chronic hyperuricemia [2]. It
affects 1-2% of adults in developed countries [2] and is
considered an independent risk factor for cardiovascular
disease [3]. Uric acid values higher than 7.0 mg/dl is a
risk factor for the development of gout [3].
Renal calculi
Renal calculi are formed by calcium salts deposited on
an organic matrix of oxalate or urate. Their formation
occurs in the glomerular filtrate in acid (oxalate or
urate) or alkaline (carbonates and phosphates) pH in the
presence of high calciuria (hyperparathyroidism or bone
demineralization). They are usually formed and then
dissolved, but under abnormal pH variation or filtrate
concentration conditions, they may remain until excre-
tion [30].
The contribution of UA to renal stone formation has
an important role in progressive renal failure [57].
Metabolic syndrome and body composition
Meta-analysis has recently shown that UA elevation is
related to an increase in (coronary artery disease) infarc-
tion and mortality events [1], and epidemiological stu-
dies showed that UA is an independent risk factor for
cardiovascular diseases [5,10], particularly in hyperten-
sive and diabetic individuals [21]. It is also speculated
that UA is one of the determinants of the metabolic
syndrome [22]. Individuals with high UA levels have an
odds ratio of 1.6-fold higher for developing MS [58].
UA is associated with Metabolic Syndrome [59] and
its components [60], obesity, dyslipidemia, hypertension
[18], insulin resistance (metabolic syndrome), increased
C-reactive protein (PCR) concentration [23] and
endothelial dysfunction [20], or even, to risk factors for
cardiovascular diseases [7,17,19].
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resistance, probably because hyperisulinemia would
cause lower renal UA excretion [61]. Additionally, insu-
lin could indirectly act on UA, since there is an associa-
tion between hyperinsulinemia and hypertriglyceridemia.
Some studies show that high concentrations of plasma
triglycerides are related to hyperuricemia [58,62-64].
There are some explanations for such relation, and one
of them is that during triglycerides (TG) synthesis there
would be a greater need for NADPH [62]. The synthesis
of fatty acids in the liver is associated with the de novo
synthesis of purine, thus accelerating UA production
[65].
Chen et al. (2007) [58] observed negative correlation
between HDL-c and UA. The likely mechanism is the
relationship between decreased HDL-C and insulin
resistance [66]. Confirming this hypothesis, our research
g r o u ps h o w e dt h a tw h e na d j u s t e df o rt h eo t h e rM S
components, the relation between UA and HDL-c is lost
[67].
In the adipose tissue, there is adipokine production,
including that of leptin. One possible explanation for
the association between higher waist circumference and
hyperuricemia were suggested by Bedir et al. (2003) [68]
and Fruehwald-Schultes et al. (1999) [69] which studies
found that UA serum concentrations are independently
related to leptin concentration, thus suggesting that
would be a pathogenic factor responsible for UA
increase in obese patients [58].
Some authors report UA to be responsible for blood
pressure increase, and others show arterial hypertension
(AH) to be a risk factor for hiperuricemia. UA inhibits
the bioavailability of nitric oxide, which is a vasodilator
[70], and, on the other hand, AH would lead to vascular
disease and increase renal vascular resistance. Both of
these processes reduce renal flow, thus increasing urate
resorption [71].
A recent study showed an inverse relation between
muscle mass (MM) and UA in healthy individuals older
than 40 years [72]. Chronic elevation of UA concentra-
tions would be a causal factor for sarcopenia, especially
through increased inflammation and oxidative stress
[72,73]. The activation of the xanthine oxidase metabolic
pathway, which increases UA production and the super-
oxide radical [74] could elevate the reactive oxygen spe-
cies (ROS) and it could be the main mechanism for the
reduction of MM. Furthermore, UA exerts a pro-inflam-
matory effect, thus stimulating the production of inter-
leukin-1, interleukin-6 the tumor necrosis factor which
also can influence the muscle mass [75].
Uricemia as a protective factor
It is not known whether UA would be a causal factor or
an antioxidant protective response against oxidative
stress [76]. While chronic high UA concentrations are
associated to increased risk for CAD, acute elevations
seem to provide antioxidant protection [77]. UA contri-
butes to > 50% of the antioxidant capacity of the blood
[78]. Furthermore, the UA has a protective action in
vitamins C and E [79] with the stabilizing activities in
these vitamins [79,80] and the presence of ascorbic acid
in plasma is required for the antioxidant effect of UA
[80]. Also, it has a direct effect on the inhibition of free
radicals such as peroxyl radical and peroxynitrite, pro-
tecting the cell membrane and DNA [81,82].
Most authors do not consider UA as a detrimental
factor to the body health, because of its antioxidant
function [8,83]. The antioxidant activity of UA also
occurs in the brain [84], being a protector for several
disease such as multiple sclerosis and neurodegenerative
disease. Higher concentration of UA is associated with
lower risk of development of Parksons disease and a
favorable effect at the disease progression mainly [85].
Conclusions
Several factors are associated as cause and consequences
of high UA concentration. Higher waist circumference
and BMI are associated with higher insulin resistance
and leptin production, and both reduce renal uric acid
excretion, thus increasing its concentration. HDL-c con-
centration is negatively associated to insulin resistance,
what can influence its negative correlation to uric acid.
Obese individuals usually have Metabolic Syndrome
diagnostic, which can also increase uric acid serum con-
centrations due to synthesis increase (triglycerides - TG
concentration) and lower excretion (arterial hyperten-
sion - AH) (Figure 1).
Additionally, obesity and muscle mass (MM) reduc-
tion are associated with low-intensity chronic inflamma-
tion, and uric acid levels can increase in order to
protect the organism against the moderate oxidative
stress resulting from this situation. Low muscle mass
(sarcopenia) is negatively associated with uric acid,
However, it has not yet been clarified what the cause or
effect is. Probably, oxidative stress produced by exces-
sive uric acid can influence muscle mass reduction. The
role played by diet on hyperuricemia has not yet been
fully clarified, but high intake of fructose-rich industria-
lized food and high alcohol intake (particularly beer)
seem to influence uricemia. The main mechanism of
excretion of urate concentrations occurs by means of
renal excretion; hence, glomerular function markers
(urea and creatinine) are positively associated with uric
acid (Figure 1).
Furthermore, there is still no consensus if UA is a
protective or a risk factor, however, it seems that the
quantity and the duration of the concentration of the
uric acid in the blood is essential for this answer. Acute
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chronic elevation a risk factor.
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